Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.

ABSTRACT:

Background

Circulating blasts (peripheral blood [PB] blasts) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts have incremental value with regard to patient prognostication is unclear. Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.

Methods

The authors retrospectively studied 1316 patients with myelofibrosis who presented at their institution between 1984 and 2018 and had available PB and BM blasts.

Results

The PB blast percentage influenced overall survival (OS) only among patients who had BM blasts <5%, with a median OS of 64 months for patients with 0% P

SUBMITTER: Masarova L 

PROVIDER: S-EPMC7875207 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature